eligibility_summary
Adults ≥19 with unresectable, GPC3+ HCC refractory to 1–2 prior standard lines, ≥1 measurable lesion (mRECIST v1.1), Child-Pugh A or B7, ECOG 0–1, life expectancy ≥3 months, adequate marrow/liver/renal function, WOCBP negative test and contraception, consent required. Exclude hepatic encephalopathy, brain/spinal mets, ≥50% liver involvement, severe ascites, HIV, active HBV/HCV (unless controlled), uncontrolled infection, organ transplant, recent other cancers, severe cardiac/renal/resp disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: EU307, an autologous glypican-3 (GPC3)–targeted chimeric antigen receptor T‑cell (CAR-T) therapy (biological/cellular immunotherapy). Mechanism: Patient T cells are engineered to express a CAR that binds GPC3 on tumor cells, antigen engagement activates CAR signaling (CD3ζ with costimulation), driving T-cell activation, cytokine release, proliferation, and perforin/granzyme-mediated cytotoxic killing. Targets: GPC3-positive hepatocellular carcinoma cells, immune effector pathway is CAR-T–mediated cytotoxicity against GPC3-expressing tumors. Study: Phase 1, open-label, dose-escalation, single-arm, single IV dose in advanced GPC3+ HCC post standard therapy failure.